Drugs for Skin Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 160)
| # |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
| 1 |
|
Triamcinolone |
Approved, Vet_approved |
Phase 4,Phase 2 |
|
124-94-7 |
31307
|
|
Synonyms:
(8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11b,16a,17a,21-Tetrahydroxy-9a-fluoro-1,4-pregnadiene-3,20-dione
11beta,16alpha,17alpha,21-Tetrahydroxy-9alpha-fluoro-1,4-pregnadiene-3,20-dione
11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione
11β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione
124-94-7
4-08-00-03629 (Beilstein Handbook Reference)
83474-03-7
9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d
9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone
9a-fluoro-11b,16a,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione
9a-fluoro-11b,16a,17a,21-Tetrahydroxypregna-1,4-diene-3,20-dione
9a-fluoro-16a-Hydroxyprednisolone
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9alpha-fluoro-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-fluoro-11beta,16alpha,17alpha,21-Tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-fluoro-16alpha-Hydroxyprednisolone
9alpha-Fluoro-16alpha-hydroxyprednisolone
9-alpha-Fluoro-16-alpha-hydroxyprednisolone
9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-fluoro-11b,16a,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione
9-fluoro-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-11β,16α,17α,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-16α-hydroxyprednisolone
AC1L1LDH
AC1Q5HJC
AC-2072
Adcortyl
Aristocort
Aristocort A
Aristocort Tablets
Aristogel
Aristospan
Azmacort
Bio-0662
BPBio1_000154
BRD-K77554836-001-03-3
BRN 2341955
BSPBio_000140
C21H27FO6
Celeste
CHEMBL1451
CID31307
Cinolone
Cinolone-T
CL 19823
D00385
D014221
DB00620
Delphicort
droxypregna-1,4-diene-3,20-dione
EINECS 204-718-7
EU-0101179
Fluoxiprednisolone
Fluoxyprednisolone
Flutex
Fougera
HMS1568G22
HMS2090D12
HSDB 3194
ione
Kenacort
Kenacort (TN)
Kenacort-A
Kenacort-Ag
Kenacort-AG
Kenalog
Kenalog in Orabase
|
Kenalog-10
Kenalog-40
Kenalog-H
Ledercort
Lopac0_001179
LS-698
MLS000028542
MLS001066543
MLS002695935
MolPort-002-528-981
Mycolog
Nasacort
Nasacort Aq
Nasacort Hfa
NCGC00021580-03
NCGC00021580-04
NCGC00021580-05
NCGC00021580-06
NCGC00021580-07
nchembio.2007.53-comp7
NCI60_000750
NSC 13397
NSC13397
Omcilon
Omicilon
Oracort
Oralone
Orion
Polcortolon
Pregna-1,4-diene-3,20-dio
Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha)
Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy- (8CI)
Prestwick_438
Prestwick0_000120
Prestwick1_000120
Prestwick2_000120
Prestwick3_000120
Rodinolone
S1933_Selleck
Sk-Triamcinolone
SK-Triamcinolone
SMP1_000300
SMR000058333
SPBio_002079
T6376_SIGMA
Tiamcinolonum
Tiamcinolonum [INN-Latin]
Triacet
Triacort
Triamcet
Triamcinalone
Triamcinlon
Triamcinolon
Triamcinolona
Triamcinolona [INN-Spanish]
triamcinolone
Triamcinolone (JP15/USP/INN)
TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7))
Triamcinolone [USAN:INN:BAN:JAN]
Triamcinolone acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Triamcinolonum
Triamcinolonum [INN]
Triam-Tablinen
Triatex
Tricortale
Triderm
Trilone
Tri-Nasal
Tristoject
Trymex
UNII-1ZK20VI6TY
Vetalog
Volon
Volon A
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ GQ
ZINC03882036
|
|
| 2 |
|
Fluorouracil |
Approved |
Phase 4,Phase 2 |
|
51-21-8 |
3385
|
|
Synonyms:
1004-03-1
1-fluoro-1h-pyrimidine-2,4-dione
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 Fluorouracil
5 Fluorouracil biosyn
5 FU lederle
5 FU Lederle
5 FU medac
5 HU hexal
5 HU Hexal
51-21-8
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-fluoropyrimidine-2,4(1H,3H)-dione
5-Fluoropyrimidine-2,4-dione
5-fluorouracil
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5FU
5-FU
5-FU (TN)
5-FU lederle
5-FU Lederle
5-FU medac
5-HU hexal
5-HU Hexal
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
AI3-25297
AKOS000119162
AKOS003237897
Allergan brand OF fluorouracil
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
biosyn Brand of Fluorouracil
Biosyn brand OF fluorouracil
BSPBio_002048
C07649
C4H3FN2O2
Carac
Carac (TN)
Carzonal
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
Cinco FU
CPD000038082
CPD0-1327
CSP Brand of Fluorouracil
CSP Brand OF fluorouracil
Cytosafe
D005472
D00584
Dakota brand OF fluorouracil
Dakota Brand of Fluorouracil
Dakota, fluorouracile
Dakota, Fluorouracile
DB00544
Dermatech brand OF fluorouracil
Dermatech Brand of Fluorouracil
Dermik brand OF fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
EINECS 200-085-6
EU-0100536
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
Ferrer brand OF fluorouracil
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
fluoro Uracile icn
Fluoro Uracile ICN
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
fluorouracil
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil [USAN:INN:BAN:JAN]
Fluorouracil gry
Fluorouracil GRY
Fluorouracil mononitrate
Fluorouracil Mononitrate
Fluorouracil monopotassium salt
Fluorouracil Monopotassium Salt
Fluorouracil monosodium salt
Fluorouracil Monosodium Salt
Fluorouracil potassium salt
Fluorouracil Potassium Salt
Fluorouracil teva brand
Fluorouracil Teva Brand
Fluorouracile
Fluoro-uracile
Fluorouracile [DCIT]
|
Fluorouracile dakota
Fluorouracile Dakota
fluoro-Uracile icn
Fluoro-Uracile ICN
Fluorouracil-gry
Fluorouracil-GRY
Fluorouracilo
Fluoro-uracilo
Fluorouracilo [INN-Spanish]
fluorouracilo Ferrer far
Fluorouracilo Ferrer Far
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
FT-0082524
Ftoruracil
FU
Gry brand OF fluorouracil
Gry Brand of Fluorouracil
haemato Brand OF fluorouracil
Haemato Brand of Fluorouracil
haemato Fu
Haemato fu
haemato-Fu
Haemato-fu
Hexal brand OF fluorouracil
Hexal Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
I07-0022
ICN brand OF fluorouracil
ICN Brand of Fluorouracil
IDI1_000054
IN1335
inhibits thymilidate synthetase
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
Lopac0_000536
Lopac-F-6627
LS-153
medac Brand of Fluorouracil
Medac brand OF fluorouracil
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
nchembio.90-comp3
nchembio809-comp6
NCI60_001652
Neocorp brand OF fluorouracil
Neocorp Brand of Fluorouracil
Neofluor
NINDS_000054
NSC 19893
NSC19893
NSC-19893
Onkofluor
Onkoworks brand OF fluorouracil
Onkoworks Brand of Fluorouracil
Pharmachemie brand OF fluorouracil monosodium salt
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
ribosepharm Brand of Fluorouracil
Ribosepharm brand OF fluorouracil
Riemser brand OF fluorouracil
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche brand OF fluorouracil
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
Spectrum_000841
SPECTRUM1500305
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
STK297802
T5233394
tetratogen
Teva brand OF fluorouracil
Teva Brand of Fluorouracil
Timazin
TL8006093
U 8953
U-8953
Ulup
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
WLN: T6MVMVJ EF
ZINC00897110
|
|
| 3 |
|
Acitretin |
Approved |
Phase 4,Phase 2,Not Applicable |
|
55079-83-9 |
5284513
6437841
|
|
Synonyms:
(2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid
(2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid
(all-e)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid
(all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid
13-cis-Acitretin
13-cis-Etretin
44707_FLUKA
44707_SIGMA
54757-46-9
55079-83-9
9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid
9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid
AC1NR4LJ
AC1Q5T6I
AC-4702
Acetretin
Acitretin
Acitretin (USAN/INN)
Acitretin [USAN:INN:BAN]
Acitretin andreu brand
Acitretin roche brand
Acitretin, (Z,e,e,e)-isomer
Acitretina
Acitretina [Spanish]
Acitretine
Acitretine [French]
Acitretinum
Acitretinum [Latin]
all-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid
all-trans-Acitretin
Andreu brand OF acitretin
BIDD:GT0617
Bio-0002
CCRIS 5534
CHEBI:50173
CHEMBL1131
|
CID5284513
CPD000499573
D02754
EINECS 259-474-4
Etretin
FT-0082892
Hoffmann la roche brand OF acitretin
Hoffmann-la roche brand OF acitretin
HSDB 7187
Isoacitretin
Isoetretin
LS-96920
MLS001076667
MolPort-003-925-892
NCGC00163127-01
NCGC00163127-02
Neotigason
Retinoid etretin
Ro 10-1670
Ro 10-1670/000
Ro 13-7652
Ro-10-1670
Ro-10-1670/000
Ro-13-7652
Roche brand OF acitretin
S1368_Selleck
SAM002589973
SBB064171
SMR000499573
Soriatane
Soriatane (TN)
Soriatane, Acitretin
Spectrum5_002065
TMMP
U0279
UNII-LCH760E9T7
|
|
| 4 |
|
Immunologic Factors |
|
Phase 4,Phase 2,Phase 1,Not Applicable |
|
|
|
| 5 |
|
Tin Fluorides |
|
Phase 4 |
|
|
|
| 6 |
|
Triamcinolone hexacetonide |
|
Phase 4,Phase 2 |
|
|
|
| 7 |
|
Antimetabolites, Antineoplastic |
|
Phase 4,Phase 2 |
|
|
|
| 8 |
|
Immunosuppressive Agents |
|
Phase 4,Phase 2,Phase 1,Not Applicable |
|
|
|
| 9 |
|
Dermatologic Agents |
|
Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 10 |
|
triamcinolone acetonide |
|
Phase 4,Phase 2 |
|
|
|
| 11 |
|
Antimetabolites |
|
Phase 4,Phase 3,Phase 2 |
|
|
|
| 12 |
|
Triamcinolone diacetate |
|
Phase 4,Phase 2 |
|
|
|
| 13 |
|
Hormones |
|
Phase 4,Phase 3,Phase 2 |
|
|
|
| 14 |
|
Hormone Antagonists |
|
Phase 4,Phase 3,Phase 2 |
|
|
|
| 15 |
|
Hormones, Hormone Substitutes, and Hormone Antagonists |
|
Phase 4,Phase 3,Phase 2 |
|
|
|
| 16 |
|
Keratolytic Agents |
|
Phase 4,Phase 2,Not Applicable |
|
|
|
| 17 |
|
Carboplatin |
Approved |
Phase 3 |
|
41575-94-4 |
10339178
38904
498142
|
|
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
azanide
Blastocarb
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
Carbopaltin
Carboplat
carboplatin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Carbosin
Carbotec
Cbdca
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
Cyclobutane-1,1-dicarboxylate
cyclobutane-1,1-dicarboxylic acid
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
|
EINECS 255-446-0
Ercar
EU-0100230
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
IUPAC: Azane
JM 8
JM8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
Lopac0_000230
Lopac-C-2538
LS-117689
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
Nealorin
Neocarbo
NINDS_000892
NSC 201345
NSC 241240
NSC201345
NSC241240
NSC-241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
platinum(2+)
Platinum(II), (1, 1-cyclobutanedicar
Platinum, {diammine[1,1-cyclobut
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Ribocarbo
S1215_Selleck
SPBio_000716
Spectrum_001529
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
UNII-BG3F62OND5
|
|
| 18 |
|
Darbepoetin alfa |
Approved, Investigational |
Phase 3 |
|
11096-26-7, 209810-58-2 |
|
|
Synonyms:
|
|
Darbepoetin alfa,recombinant
|
|
| 19 |
|
Vemurafenib |
Approved |
Phase 3,Phase 1,Phase 2,Not Applicable |
|
918504-65-1 |
23252090
42611257
|
|
Synonyms:
BRAF(V600E) Kinase Inhibitor RO5185426
PLX4032
PLX-4032
R05185426
|
RG7204
RO5185426
vemurafenib
Zelboraf
|
|
| 20 |
|
Tamoxifen |
Approved |
Phase 3 |
|
10540-29-1 |
2733526
|
|
Synonyms:
(Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
(Z)-2-(Para-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC)
(Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE
(Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
,citrate
10540-29-1
1-p-.beta.-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-b-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-β-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-P-b-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-P-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-P-β-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1ya4
2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine
54965-24-1 (citrate)
AC1MBZ3R
apo-Tamox
Apo-Tamox
BIDD:ER0008
BIDD:GT0009
BIDD:PXR0003
BPBio1_000278
BRD-K93754473-001-02-9
BRD-K93754473-048-05-3
BSPBio_000252
BSPBio_001150
BSPBio_001982
C07108
C26H29NO
CCRIS 3275
CHEBI:41774
CHEMBL83
CID2733526
Citofen
Citrate, tamoxifen
cMAP_000044
Crisafeno
D08559
DB00675
Diemon
EINECS 234-118-0
Gen-tamoxifen
Gen-Tamoxifen
HMS1362J11
HMS1792J11
HMS1990J11
HMS2090N08
HSDB 6782
ICI 47699
ICI-46,474
ICI-47699
IDI1_000258
IDI1_002170
Istubol
Kessar
L024126
Lopac0_001203
LS-393
MLS001332535
MLS001332536
|
MolPort-003-850-384
NCGC00024928-01
NCGC00024928-03
NCGC00024928-04
NCGC00024928-05
NCGC00024928-07
NCGC00024928-08
NCGC00024928-09
NCGC00024928-12
nchembio.140-comp7
nchembio.76-comp1
nchembio732-comp3
Noltam
Nolvadex
Nolvadex-D
Nourytam
Novaldex
Novo-Tamoxifen
NSC727681
Oncomox
Pms-Tamoxifen
PMS-Tamoxifen
Prestwick2_000146
Prestwick3_000146
QTL1_000079
Retaxim
Savient brand OF tamoxifen citrate
SMR000059172
Soltamox
Spectrum5_001417
Spectrum5_002043
ST50511785
T5648_SIGMA
Tamizam
Tamofen
Tamone
Tamoplex (TN)
Tamoxasta
Tamoxen
tamoxifen
Tamoxifen
Tamoxifen (INN)
TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1))
Tamoxifen (TN)
Tamoxifen (Z)
Tamoxifen [INN:BAN]
Tamoxifen and its salts
Tamoxifen citrate
Tamoxifen Citrate
Tamoxifene
Tamoxifène
Tamoxifene [INN-French]
Tamoxifeno
Tamoxifeno [INN-Spanish]
Tamoxifenum
Tamoxifenum [INN-Latin]
Tocris-0999
Tomaxithen
TRANS FORM OF TAMOXIFEN
trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
trans-Tamoxifen
Trans-Tamoxifen
UNII-094ZI81Y45
UPCMLD-DP027
Valodex
Zemide
Zitazonium
|
|
| 21 |
|
Anastrozole |
Approved, Investigational |
Phase 3 |
|
120511-73-1 |
2187
|
|
Synonyms:
.alpha.,alpha.,.alpha.',.alpha.'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
1,3-benzenediacetonitrile, a, a, a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)
120511-73-1
2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile)
2,2'-(5-(1H-1,2,4-Triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile)
2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
a,a,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
AC1L1D49
AC-4234
alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
alpha,alpha,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
anastrazole
Anastrazole
Anastrole
Anastrozol
anastrozole
Anastrozole (JAN/USAN/INN)
Anastrozole [USAN:INN:BAN]
Arimidex
Arimidex (TN)
Arimidex (Zeneca)
Arimidex, Anastrozole
Asiolex
Astra brand of anastrozole
Astra brand OF anastrozole
AstraZeneca brand of anastrozole
AstraZeneca brand OF anastrozole
C08159
C090450
C17H19N5
|
CHEBI:2704
CHEMBL1399
CID2187
CPD000466301
D00960
DB01217
HMS2052M11
HMS2089N10
HSDB 7462
I06-0021
ICI D1033
ICI-D 1033
ICI-D1033
LS-29563
MLS000759396
MLS001424217
MolPort-005-933-078
NCGC00164619-01
NSC719344
S1188_Selleck
SAM001246525
SBB066057
SMR000466301
UNII-2Z07MYW1AZ
ZD 1033
ZD1033
ZD-1033
Zeneca brand of anastrozole
Zeneca brand OF anastrozole
Zeneca ZD 1033
ZINC00000941
α,α,alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
|
|
| 22 |
|
Pitavastatin |
Approved |
Phase 3 |
|
147511-69-1, 147526-32-7 |
5282452
6366718
|
|
Synonyms:
( )-(3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoic acid
(3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid
(3R,5S,6E)-7-(2-Cyclopropyl-4-(p-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoic acid
(3R,5S,E)-7-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoate
(E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid
111GE002
147511-69-1
147526-32-7
2C25H23FNO4.Ca
AC1NR03G
AC1NR03J
AKOS005145916
Alipza
Bis((3R,5S,6E)-7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoate), monocalcium salt
C13334
calcium (E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate
CCRIS 8652
CID5282451
CID5282452
D01862
Itavastatin
Itavastatin calcium
KS-1220
Livalo
|
Livalo (TN)
Livalo, Pitavastatin calcium
Livazo
LS-190698
LS-74594
LS-74595
MolPort-006-822-984
Nisvastatin
NK 104
NK-104
NKS-104
P 872441
P-872441
Pitavastatia
Pitavastatin
Pitavastatin [INN]
Pitavastatin calcium
Pitavastatin calcium (JAN)
Pitavastatin hemicalcium
Pitavastatine
Pitavastatinum
S1759_Selleck
ZINC01534965
|
|
| 23 |
|
Ornithine |
Approved, Nutraceutical |
Phase 3,Phase 2 |
|
3184-13-2, 70-26-8 |
6262
|
|
Synonyms:
(+)-S-Ornithine
(S)-2,5-Diaminopentanoate
(S)-2,5-Diaminopentanoic acid
(S)-2,5-Diaminovalerate
(S)-2,5-diaminovaleric acid
(S)-2,5-Diaminovaleric acid
(S)-a,D-Diaminovalerate
(S)-a,D-Diaminovaleric acid
(S)-a,delta-Diaminovalerate
(S)-a,delta-Diaminovaleric acid
(S)-a,δ-diaminovalerate
(S)-a,δ-diaminovaleric acid
(S)-alpha,delta-Diaminovalerate
(S)-alpha,delta-Diaminovaleric acid
(S)-ornithine
(S)-Ornithine
(S)-α,δ-diaminovalerate
(S)-α,δ-diaminovaleric acid
2,5 Diaminopentanoic acid
|
2,5-Diaminopentanoic acid
5-amino-L-Norvaline
L-(-)-Ornithine
levo-ornithine
L-Ornithine
Ornithine dihydrochloride, (L)-isomer
Ornithine hydrochloride, (D)-isomer
Ornithine hydrochloride, (DL)-isomer
Ornithine hydrochloride, (L)-isomer
Ornithine monoacetate, (L)-isomer
Ornithine monohydrobromide, (L)-isomer
Ornithine monohydrochloride, (D)-isomer
Ornithine monohydrochloride, (DL)-isomer
Ornithine phosphate (1:1), (L)-isomer
Ornithine sulfate (1:1), (L)-isomer
Ornithine, (D)-isomer
Ornithine, (DL)-isomer
Ornithine, (L)-isomer
|
|
| 24 |
|
Citric Acid |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
77-92-9 |
311
|
|
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-carboxy-3-hydroxypentane-1,5-dioic acid
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
|
Citretten
Citric acid monoglyceride
Citric acid monohydrate
Citric acid, anhydrous
Citric Acid, Anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
H3Cit
Hydrocerol a
Kyselina citronova
Monohydrate, citric acid
Suby g
Uralyt u
uro-Trainer
|
|
| 25 |
|
Anti-Infective Agents |
|
Phase 3,Phase 1,Phase 2 |
|
|
|
| 26 |
|
Antiparasitic Agents |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
| 27 |
|
Antiprotozoal Agents |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
| 28 |
|
Hematinics |
|
Phase 3 |
|
|
|
| 29 |
|
Bone Density Conservation Agents |
|
Phase 3 |
|
|
|
| 30 |
|
Estrogen Receptor Modulators |
|
Phase 3 |
|
|
|
| 31 |
|
Antineoplastic Agents, Hormonal |
|
Phase 3 |
|
|
|
| 32 |
|
Aromatase Inhibitors |
|
Phase 3 |
|
|
|
| 33 |
|
Steroid Synthesis Inhibitors |
|
Phase 3 |
|
|
|
| 34 |
|
Selective Estrogen Receptor Modulators |
|
Phase 3 |
|
|
|
| 35 |
|
Estrogen Antagonists |
|
Phase 3 |
|
|
|
| 36 |
|
Citrate |
|
Phase 3 |
|
|
|
| 37 |
|
Estrogens |
|
Phase 3 |
|
|
|
| 38 |
|
Estrogen Receptor Antagonists |
|
Phase 3 |
|
|
|
| 39 |
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors |
|
Phase 3 |
|
|
|
| 40 |
|
Anticholesteremic Agents |
|
Phase 3 |
|
|
|
| 41 |
|
Hypolipidemic Agents |
|
Phase 3 |
|
|
|
| 42 |
|
Lipid Regulating Agents |
|
Phase 3 |
|
|
|
| 43 |
|
Peginterferon alfa-2a |
Approved, Investigational |
Phase 1, Phase 2,Phase 2 |
|
198153-51-4 |
5360545
|
|
Synonyms:
198153-51-4
D02747
Pegasys
Pegasys (TN)
Peginterferon alfa-2a
|
Peginterferon alfa-2a (genetical recombination)
Peginterferon alfa-2a (genetical recombination) (JAN)
Peginterferon alfa-2a (USAN/INN)
Pegylated interferon alfa-2a
Pegylated interferon alpha2a
|
|
| 44 |
|
Gefitinib |
Approved, Investigational |
Phase 1, Phase 2,Phase 2 |
|
184475-35-2 |
123631
|
|
Synonyms:
184475-35-2
4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
4-(3'-chloro-4'-fluoroanilino)-7-Methoxy-6-(3-morpholinopropoxy)quinazoline
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
AC-1556
AC1L3X0A
AKOS000280752
BCB03_000781
Bio-0046
C419708
CCRIS 9011
CHEBI:49668
CHEMBL939
CID123631
CU-00000000396-1
D01977
DB00317
DB07998
EC-000.2409
EN002708
FT-0081035
Gefitini
gefitinib
Gefitinib
Gefitinib (JAN/USAN/INN)
Gefitinib [USAN]
Gefitinib, Iressa, ZD1839
Gelfitinib
HMS2089B19
I01-1227
IRE
|
Iressa
Iressa (TN)
Iressa(TM)
Irressat
K00240
KBioSS_002241
Kinome_3321
Kinome_3322
LS-139916
MolPort-000-883-335
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-chloro-4-Fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
N-(3-chloro-4-Fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
NCGC00159455-02
NCGC00159455-03
nchembio.117-comp18
nchembio866-comp14
NSC715055
S1025_Selleck
STK621310
UNII-S65743JHBS
ZD 1839
ZD1839
ZD-1839
ZD-1839, Iressa, Gefitinib
ZINC19632614
|
|
| 45 |
|
Dasatinib |
Approved, Investigational |
Phase 2 |
|
302962-49-8 |
3062316
|
|
Synonyms:
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
(18F)-N-(2-chloro-6-Methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
1N1
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
302962-49-8
AC1MI3ET
AC1Q2P0C
AmbotzLS-1203
anh. dasatinib
Anh. dasatinib
Anhydrous dasatinib
BCB03_000715
BMS 354825
BMS dasatinib
BMS Dasatinib
BMS354825
BMS-354825
BMS-354825, Sprycel, BMS354825, Dasatinib
C488369
CHEBI:49375
CHEMBL1421
CID3062316
D03658
dasatinib
Dasatinib
Dasatinib (anh.)
dasatinib (anhydrous)
Dasatinib (USAN)
Dasatinib [USAN]
Dasatinib anhydrous
Dasatinib, BMS 354825
|
dasatinibum
Dasatinibum
DB01254
EC-000.2122
EN002710
FT-0084503
I14-1972
Kinome_3650
LS-186641
LS-187028
LS-187773
MolPort-003-846-143
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
N-(2-chloro-6-METHYLPHENYL)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-chloro-6-Methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
NCGC00181129-01
nchembio.117-comp11
nchembio.162-comp4
nchembio.332-comp1
NSC732517
NSC-732517
S1021_Selleck
Sprycel
SPRYCEL (TN)
Spyrcel
UNII-X78UG0A0RN
|
|
| 46 |
|
Cetuximab |
Approved |
Phase 2,Phase 1,Not Applicable |
|
205923-56-4 |
56842117
2333
|
|
Synonyms:
205923-56-4
Anti EGFR
cetuximab
Cetuximab
Cétuximab
Cetuximab (genetical recombination)
Cetuximab (genetical recombination) (JAN)
|
Cetuximab (USAN/INN)
Cetuximabum
D03455
Erbitux
Erbitux (TN)
IMC-C225
Immunoglobulin G 1 (human-mouse monoclonal C 225 gamma 1 - chain anti-human epidermal growt factor receptor), disulfide wit human-mouse monoclonal C 225 kappa - chain, dimer
|
|
| 47 |
|
Aminolevulinic acid |
Approved |
Phase 2,Not Applicable,Early Phase 1 |
|
106-60-5 |
137
|
|
Synonyms:
106-60-5
35BEC718-C970-426A-9859-BF58284C60B4
5 Aminolaevulinate
5 Aminolevulinate
5451-09-2
5-ALA
5-amino-4-oxo-Pentanoate
5-amino-4-Oxopentanoate
5-Amino-4-oxopentanoate
5-amino-4-oxo-Pentanoic acid
5-amino-4-Oxopentanoic acid
5-Amino-4-oxopentanoic acid
5-amino-4-Oxovalerate
5-amino-4-Oxovaleric acid
5-Amino-4-oxovaleric acid
5-Aminolaevulinate
5-Aminolaevulinic acid
5-amino-levulinate
5-amino-Levulinate
5-Aminolevulinate
5-amino-Levulinic acid
5-Aminolevulinic acid
AC-054
AC1L18K9
Acid hydrochloride, aminolevulinic
Acid, aminolevulinic
Acid, Delta-aminolevulinic
AKOS003587520
Aladerm
Aminolevulinate
Aminolevulinic
amino-Levulinic acid
Aminolevulinic acid
Aminolevulinic acid hydrochloride
Bertek brand OF aminolevulinic acid hydrochloride
BIDD:GT0260
BSPBio_003407
C00430
CCRIS 8958
CHEBI:17549
CHEMBL601
CID137
CPD000857229
D07567
|
dALA
DALA
DB00855
Delta Aminolevulinic acid
delta-ALA
delta-Aminolevulinate
delta-aminolevulinic acid
delta-Aminolevulinic acid
DivK1c_006954
EINECS 203-414-1
Hydrochloride, aminolevulinic acid
I14-10101
KBio1_001898
KBio2_002062
KBio2_004630
KBio2_007198
KBio3_002627
KBioGR_001176
KBioSS_002062
Kerastick
Levulan
Levulinic acid, 5-amino- (8CI)
LMFA01100055
LS-101793
MLS001333097
MLS001333098
MolPort-001-788-423
NCGC00178086-01
Pentanoic acid, 5-amino-4-oxo- (9CI)
SAM002589919
SMR000857229
SPBio_001843
SpecPlus_000858
Spectrum_001582
Spectrum2_001662
Spectrum3_001654
Spectrum4_000618
Spectrum5_001505
ST50819610
UNII-88755TAZ87
δ-ala
δ-ALA
δ-aminolevulinate
δ-aminolevulinic acid
|
|
| 48 |
|
Aldesleukin |
Approved |
Phase 1, Phase 2 |
|
85898-30-2, 110942-02-4 |
|
|
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
Interleukin-2 aldesleukin
|
Interleukin-2(2-133),125-ser
Recombinant interleukin-2 human
|
|
| 49 |
|
Isotretinoin |
Approved |
Phase 2,Not Applicable |
|
4759-48-2 |
5538
5282379
|
|
Synonyms:
(13-cis)-Retinoate
(13cis)-retinoic acid
(13-cis)-Retinoic acid
(2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
(2Z,4E6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid
(7E,9E,11E,13Z)-Retinoate
(7e,9e,11e,13Z)-Retinoic acid
(7E,9E,11E,13Z)-retinoic acid
(7E,9E,11E,13Z)-Retinoic acid
13 cis retinoic acid
13 cis Retinoic acid
13 Cis-Retinoic Acid
13-cis RA
13-cis retinoic acid
13-cis-Retinoate
13-cis-Retinoic acid
13-cis-Vitamin a acid
13-cis-Vitamin A acid
13-RA
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-cis-4-trans-6-trans-8-trans-nonatetraenoic acid
4-09-00-02388 (Beilstein Handbook Reference)
4759-48-2
97950-17-9
AC-15388
AC1NQZZ4
Accutane
Accutane (TN)
Ambap302-79-4
Amnesteem
BML2-E07
BPBio1_000080
BRD-K76723084-001-05-9
BRN 1885770
BSPBio_000072
BSPBio_001331
BSPBio_003345
CCRIS 4286
CHEBI:6067
CHEMBL547
CID5282379
CIP-isotretinoin
CIP-Isotretinoin
cis-RA
cis-Retinoate
cis-Retinoic acid
Claravis
CPD000471891
D00348
D015474
EINECS 225-296-0
EU-0101081
HMS1361C13
HMS1568D14
HMS1791C13
HMS1921D08
HMS1989C13
HMS2092N07
HSDB 3929
IDI1_033801
|
Isotane
Isotretinoin
Isotretinoin (USP)
Isotretinoin [USAN:INN:BAN]
Isotretinoin Retinoic acid
Isotretinoin zinc salt, 13 cis isomer
Isotretinoin Zinc Salt, 13 cis Isomer
Isotretinoin zinc salt, 13-cis-isomer
Isotretinoin Zinc Salt, 13-cis-Isomer
Isotretinoina
Isotretinoine
Isotretinoine [INN-French]
isotretinoino
Isotretinoino
Isotretinoino [INN-Spanish]
Isotretinoinum
Isotretinoinum [INN-Latin]
Isotrex
LMPR01090021
Lopac0_001081
LS-143465
MLS001074662
MolPort-003-666-394
NCGC00094358-01
NCGC00094358-02
NCGC00094358-03
NCGC00094358-04
NCGC00094358-05
NCGC00094358-06
NCGC00094358-07
NCGC00094358-08
NCGC00094358-09
NCGC00094358-13
Neovitamin a acid
Neovitamin A acid
Prestwick_642
Prestwick2_000256
Prestwick3_000256
R 3255
R3255_SIGMA
Retinoate
Retinoic acid
Ro 4 3780
Ro 43780
Ro 4-3780
Ro-43780
Ro-4-3780
Roaccutan
Roaccutane
Roacutan
SAM002548955
SMR000471891
Sotret
Sotret (TN)
SPECTRUM1502013
Spectrum5_001795
Spectrum5_001937
Teriosal
UNII-EH28UP18IF
|
|
| 50 |
|
Pembrolizumab |
Approved |
Phase 2,Phase 1 |
|
1374853-91-4 |
|
|
Synonyms:
|
Interventional clinical trials:
(show top 50)
(show all 109)
| # |
Name |
Status |
NCT ID |
Phase |
Drugs |
| 1 |
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial |
Completed |
NCT00847912
|
Phase 4 |
5-fluorouracil;Placebo, vehicle control |
| 2 |
Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome |
Completed |
NCT00266656
|
Phase 4 |
Humatrope |
| 3 |
Acitretin Plasma Levels Under Hemodialysis |
Withdrawn |
NCT00488384
|
Phase 4 |
Chemopreventive application (Acitretin) |
| 4 |
Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and Neck |
Completed |
NCT00193895
|
Phase 3 |
Carboplatin |
| 5 |
Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer |
Completed |
NCT00005884
|
Phase 3 |
eflornithine |
| 6 |
Radiation Therapy in Treating Patients With Head and Neck Cancer |
Completed |
NCT00021125
|
Phase 3 |
|
| 7 |
Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) |
Completed |
NCT01362140
|
Phase 3 |
Darbepoetin alfa;Placebo |
| 8 |
A Study of Vemurafenib in Participants With Metastatic Melanoma |
Completed |
NCT01307397
|
Phase 3 |
Vemurafenib |
| 9 |
Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy |
Completed |
NCT00053898
|
Phase 3 |
anastrozole;tamoxifen citrate |
| 10 |
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults |
Recruiting |
NCT02344290
|
Phase 3 |
Pitavastatin;Placebo |
| 11 |
Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer |
Unknown status |
NCT02268747
|
Phase 2 |
Dacomitinib |
| 12 |
Panitumumab (Vectibix®) in Cutaneous Squamous Cell Carcinoma (SCC) |
Unknown status |
NCT01129154
|
Phase 2 |
infusions of Panitumumab |
| 13 |
Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer |
Unknown status |
NCT00423397
|
Phase 1, Phase 2 |
gefitinib |
| 14 |
Low Fat Diet to Prevent Disease Progression in Patients With Skin Cancer |
Unknown status |
NCT00003097
|
Phase 2 |
|
| 15 |
Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis) |
Completed |
NCT03333694
|
Phase 1, Phase 2 |
Cutaneous Cream application;Placebo Cutaneous Cream application |
| 16 |
Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer |
Completed |
NCT00126555
|
Phase 2 |
Gefitinib |
| 17 |
Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia |
Completed |
NCT00563290
|
Phase 2 |
dasatinib |
| 18 |
An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS) |
Completed |
NCT00652080
|
Phase 1, Phase 2 |
API 31510 |
| 19 |
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Cutaneous Squamous Cell Carcinoma In Situ |
Completed |
NCT00329121
|
Phase 2 |
PEP005 |
| 20 |
Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR |
Completed |
NCT00240682
|
Phase 2 |
cetuximab |
| 21 |
ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin |
Completed |
NCT00054691
|
Phase 2 |
Iressa |
| 22 |
A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma |
Completed |
NCT00369512
|
Phase 2 |
Erlotinib |
| 23 |
Clinical Study Assessment of SR-T100 Topical Gel Against Actinic Keratosis |
Completed |
NCT02085395
|
Phase 2 |
SR-T100 ® Gel |
| 24 |
Photodynamic Therapy in Treating Patients With Skin Cancer |
Completed |
NCT00002963
|
Phase 2 |
aminolevulinic acid hydrochloride |
| 25 |
Effect of Solanum Melongena Extract in the Treatment of Arsenical Skin Lesion |
Completed |
NCT03127670
|
Phase 2 |
Solanum melongena peel extract 0.05% |
| 26 |
Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis |
Completed |
NCT00021294
|
Phase 2 |
eflornithine;triamcinolone |
| 27 |
Photodynamic Therapy in Treating Patients With Skin Cancer |
Completed |
NCT00002975
|
Phase 2 |
aminolevulinic acid |
| 28 |
Investigation of a Behavioral Substitute for Sunbathing |
Completed |
NCT00403377
|
Phase 1, Phase 2 |
|
| 29 |
T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant |
Completed |
NCT00089180
|
Phase 2 |
liposomal T4N5 lotion |
| 30 |
Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor |
Completed |
NCT01603212
|
Phase 1, Phase 2 |
Vemurafenib;IL-2;Interferon Alpha-2b |
| 31 |
Oral Rigosertib for Squamous Cell Carcinoma |
Completed |
NCT01807546
|
Phase 2 |
rigosertib |
| 32 |
SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck |
Completed |
NCT00006361
|
Phase 2 |
semaxanib |
| 33 |
Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer |
Completed |
NCT00002506
|
Phase 2 |
isotretinoin |
| 34 |
Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma |
Recruiting |
NCT02760498
|
Phase 2 |
cemiplimab |
| 35 |
Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629) |
Recruiting |
NCT03284424
|
Phase 2 |
|
| 36 |
Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer |
Recruiting |
NCT02964559
|
Phase 2 |
|
| 37 |
Cemiplimab in Treating Participants With Recurrent Stage III-IV Head and Neck Squamous Cell Cancer Before Surgery |
Recruiting |
NCT03565783
|
Phase 2 |
|
| 38 |
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers |
Recruiting |
NCT02978625
|
Phase 2 |
|
| 39 |
Cobimetinib and Atezolizumab in Advanced Rare Tumors |
Recruiting |
NCT03108131
|
Phase 2 |
Cobimetinib;Atezolizumab |
| 40 |
Study of TVEC in Patients With Cutaneous Squamous Cell Cancer |
Recruiting |
NCT03714828
|
Phase 2 |
Injection of TVEC into target lesions - week 1-2;Injection of TVEC into target lesions 3wks after 1st injection;Injection of TVEC into target lesions 2wks after 2nd injection;Injection of TVEC into target lesions 2wks after 3rd injection |
| 41 |
Intratumoral AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors |
Recruiting |
NCT03684785
|
Phase 1, Phase 2 |
AST-008 |
| 42 |
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic |
Recruiting |
NCT02721732
|
Phase 2 |
|
| 43 |
CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer |
Recruiting |
NCT02955290
|
Phase 1, Phase 2 |
|
| 44 |
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma |
Recruiting |
NCT03082534
|
Phase 2 |
Pembrolizumab, Cetuximab |
| 45 |
Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma |
Active, not recruiting |
NCT01198028
|
Phase 2 |
Erlotinib |
| 46 |
Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma |
Active, not recruiting |
NCT02218164
|
Phase 2 |
Pegylated Interferon alpha-2b;Capecitabine;5-FU |
| 47 |
Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin |
Active, not recruiting |
NCT02883556
|
Phase 2 |
Pembrolizumab |
| 48 |
Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck |
Active, not recruiting |
NCT01979211
|
Phase 2 |
Cetuximab |
| 49 |
Preventing Squamous Cell Skin Cancer |
Enrolling by invitation |
NCT02347813
|
Phase 2 |
Pioglitazone |
| 50 |
The UNSCARRed Study: UNresctable Squamous Cell Carcinoma Treated With Avelumab and Radical Radiotherapy |
Not yet recruiting |
NCT03737721
|
Phase 2 |
|
|
